NRF2 as a Therapeutic Target in Neurodegenerative Diseases

被引:192
|
作者
Brandes, Mikah S. [1 ]
Gray, Nora E. [1 ]
机构
[1] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA
来源
ASN NEURO | 2020年 / 12卷
关键词
dementia and neurological disorders; neurodegenerative diseases; bioenergetics; NF-KAPPA-B; INDUCED OXIDATIVE STRESS; ALPHA-LIPOIC ACID; REMITTING MULTIPLE-SCLEROSIS; TRANSCRIPTION FACTOR NRF2; RELEASE DIMETHYL FUMARATE; PLACEBO-CONTROLLED PHASE-3; MILD COGNITIVE IMPAIRMENT; TRAUMATIC BRAIN-INJURY; COMPLEX I DEFICIENCY;
D O I
10.1177/1759091419899782
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Increased reactive oxygen species production and oxidative stress have been implicated in the pathogenesis of numerous neurodegenerative conditions including among others Alzheimer's disease, Parkinson's disease, Huntington's disease, Friedrich's ataxia, multiple sclerosis, and stroke. The endogenous antioxidant response pathway protects cells from oxidative stress by increasing the expression of cytoprotective enzymes and is regulated by the transcription factor nuclear factor erythroid 2-related factor 2 (NRF2). In addition to regulating the expression of antioxidant genes, NRF2 has also been shown to exert anti-inflammatory effects and modulate both mitochondrial function and biogenesis. This is because mitochondrial dysfunction and neuroinflammation are features of many neurodegenerative diseases as well NRF2 has emerged as a promising therapeutic target. Here, we review evidence for a beneficial role of NRF2 in neurodegenerative conditions and the potential of specific NRF2 activators as therapeutic agents.
引用
收藏
页数:23
相关论文
共 50 条
  • [21] Ferroptosis regulation through Nrf2 and implications for neurodegenerative diseases
    Yao Xiang
    Xiaohua Song
    Dingxin Long
    Archives of Toxicology, 2024, 98 : 579 - 615
  • [22] The Keap1–Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases
    Deshmukh P.
    Unni S.
    Krishnappa G.
    Padmanabhan B.
    Biophysical Reviews, 2017, 9 (1) : 41 - 56
  • [23] Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach
    Cuadrado, Antonio
    Manda, Gina
    Hassan, Ahmed
    Jose Alcaraz, Maria
    Barbas, Coral
    Daiber, Andreas
    Ghezzi, Pietro
    Leon, Rafael
    Lopez, Manuela G.
    Oliva, Baldo
    Pajares, Marta
    Rojo, Ana I.
    Robledinos-Anton, Natalia
    Valverde, Angela M.
    Guney, Emre
    Schmidt, Harald H. H. W.
    PHARMACOLOGICAL REVIEWS, 2018, 70 (02) : 348 - 383
  • [24] Role of NRF2 as a Therapeutic Target for RGC Protection
    Li, Qiutang
    Liu, Ting
    Rong, Yu
    Zhang, Xin
    Luk, Alvin
    Li, Bin
    MOLECULAR THERAPY, 2022, 30 (04) : 143 - 143
  • [25] Nrf2 as an emerging therapeutic target in metastatic melanoma
    Hobson, Emily
    Cowan, Jonathan
    O'Connell, Maria
    BRITISH JOURNAL OF PHARMACOLOGY, 2023, 180 (04) : 493 - 494
  • [26] Nrf2 activation as target to implement therapeutic treatments
    Bocci, Velio
    Valacchi, Giuseppe
    FRONTIERS IN CHEMISTRY, 2015, 3
  • [27] Nrf2: a potential therapeutic target for diabetic neuropathy
    Anil Kumar
    Ruchika Mittal
    Inflammopharmacology, 2017, 25 : 393 - 402
  • [28] Exploring Nrf2 as a therapeutic target in testicular dysfunction
    Damilare E. Rotimi
    Oluwafemi A. Ojo
    Tomilola D. Olaolu
    Oluyomi S. Adeyemi
    Cell and Tissue Research, 2022, 390 : 23 - 33
  • [29] Exploring Nrf2 as a therapeutic target in testicular dysfunction
    Rotimi, Damilare E.
    Ojo, Oluwafemi A.
    Olaolu, Tomilola D.
    Adeyemi, Oluyomi S.
    CELL AND TISSUE RESEARCH, 2022, 390 (01) : 23 - 33
  • [30] Nrf2: a potential therapeutic target for diabetic neuropathy
    Kumar, Anil
    Mittal, Ruchika
    INFLAMMOPHARMACOLOGY, 2017, 25 (04) : 393 - 402